Fredrik Piehl

List of Publications by Year
in descending order

280 papers	21,363 citations	18887 64 h-index	14012 133 g-index
288 all docs	288 docs citations	288 times ranked	27961 citing authors

#	Article	IF	Citations
1	Risk of depression in multiple sclerosis across disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 632-641.	1.4	5
2	ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 209-219.	1.1	5
3	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103385.	0.9	8
4	Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis. Journal of Neuroimaging, 2022, 32, 459-470.	1.0	5
5	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
6	Demyelinating events following antiâ€tumor necrosis factor alpha therapy: Rare but challenging to treat. European Journal of Neurology, 2022, 29, 2047-2055.	1.7	4
7	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	4.9	210
8	Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis. ELife, 2022, 11, .	2.8	18
9	The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors. Acta Anaesthesiologica Scandinavica, 2022, , .	0.7	9
10	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	1.4	13
11	Low-dose rituximab should be used for treating MS in resource-limited settings: Yes. Multiple Sclerosis Journal, 2022, 28, 1028-1029.	1.4	1
12	Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. Molecular Psychiatry, 2022, 27, 3247-3261.	4.1	9
13	Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients. Translational Psychiatry, 2022, 12, .	2.4	6
14	Bâ€cell repopulation dynamics and drug pharmacokinetics impact <scp>SARSâ€CoV</scp>â€2 vaccine efficacy in <scp>antiâ€CD20</scp>â€treated multiple sclerosis patients. European Journal of Neurology, 2022, 29, 3317-3328.	1.7	13
15	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	4.9	45
16	Current and emerging diseaseâ€modulatory therapies and treatment targets for multiple sclerosis. Journal of Internal Medicine, 2021, 289, 771-791.	2.7	45
17	Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 211-219.	1.1	16
18	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. Clinica Chimica Acta, 2021, 512, 74-83.	0.5	8

#	Article	IF	Citations
19	Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology, 2021, 96, e1574-e1584.	1.5	9
20	Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 493-500.	1.0	13
21	Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis. Brain, 2021, 144, 2390-2400.	3.7	11
22	Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in bloodâ€“brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study. Critical Care, 2021, 25, 103.	2.5	31
23	Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity. Journal of Internal Medicine, 2021, 290, 473-476.	2.7	2
24	Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis. Scientific Reports, 2021, 11, 7527.	1.6	9
25	Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
26	Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Multiple Sclerosis and Related Disorders, 2021, 50, 102842.	0.9	6
27	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.4	24
28	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 1197.	4.5	90
29	Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort. Neurology, 2021, 97, .	1.5	28
30	Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers. Molecular and Cellular Proteomics, 2021, 20, 100157.	2.5	15
31	Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. IScience, 2021, 24, 103078.	1.9	36
32	Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects. Scientific Reports, 2021, 11, 1669.	1.6	18
33	Association of Infectious Mononucleosis in Childhood and Adolescence With Risk for a Subsequent Multiple Sclerosis Diagnosis Among Siblings. JAMA Network Open, 2021, 4, e2124932.	2.8	15
34	Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Translational Psychiatry, 2021, 11, 566.	2.4	19
35	Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Network Open, 2021, 4, e2136697.	2.8	5
36	Neuroâ€COVID: Does severe COVIDâ€19 infection increase the risk for cognitive impairment?. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
37	Rituximab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 137-152.	1.4	46
38	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 2020, 77, 184.	4.5	342
39	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Multiple Sclerosis Journal, 2020, 26, 1532-1539.	1.4	8
40	Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Multiple Sclerosis and Related Disorders, 2020, 37, 101468.	0.9	44
41	Epilepsy in systemic lupus erythematosus: prevalence and risk factors. European Journal of Neurology, 2020, 27, 297-307.	1.7	16
42	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Annals of Clinical and Translational Neurology, 2020, 7, 139-143.	1.7	126
43	MRIâ€Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 198-204.	1.0	6
44	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.1	28
45	The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 993.	1.1	0
46	Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa152.	1.5	21
47	Is the treatment of myasthenia gravis improving?. Neurology, 2020, 95, 509-510.	1.5	0
48	Infections in patients with multiple sclerosis: A national cohort study in Sweden. Multiple Sclerosis and Related Disorders, 2020, 45, 102420.	0.9	34
49	Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis. Nature Communications, 2020, 11, 4071.	5.8	31
50	Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	22
51	A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096450.	0.5	13
52	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. Scientific Reports, 2020, 10, 18075.	1.6	19
53	Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732094776.	0.5	3
54	Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus. Annals of Neurology, 2020, 88, 1244-1250.	2.8	16

#	Article	IF	Citations
55	Neurological manifestations of coronavirus infections â€“ a systematic review. Annals of Clinical and Translational Neurology, 2020, 7, 2057-2071.	1.7	59
56	Quantification of Plasma Kynurenine Metabolites Following One Bout of Sprint Interval Exercise. International Journal of Tryptophan Research, 2020, 13, 117864692097824.	1.0	17
57	Effect of Vitamin D on Experimental Autoimmune Neuroinflammation Is Dependent on Haplotypes Comprising Naturally Occurring Allelic Variants of CIITA (Mhc2ta). Frontiers in Neurology, 2020, 11, 600401.	1.1	6
58	Rituximab, MS, and pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	59
59	Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 974.	4.5	65
60	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12952-12960.	3.3	102
61	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.5	61
62	Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl SulfoximineÂCompounds Compared to Dimethyl Fumarate. Neurotherapeutics, 2020, 17, 1142-1152.	2.1	8
63	Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e775.	3.1	16
64	Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis. Journal of Neurology, 2020, 267, 3199-3212.	1.8	31
65	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
66	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Reports, 2020, 8, 136-142.	0.3	5
67	Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis. Annals of Neurology, 2020, 87, 710-724.	2.8	42
68	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 2020, 94, e1201-e1212.	1.5	88
69	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	2.8	86
70	A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid. Bioanalysis, 2020, 12, 379-392.	0.6	28
71	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.3	18
72	Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients. Scientific Reports, 2019, 9, 11996.	1.6	13

#	Article	IF	Citations
73	Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nature Communications, 2019, 10, 3081.	5.8	97
74	GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nature Medicine, 2019, 25, 1290-1300.	15.2	140
75	Incidence of osmotic demyelination syndrome in Sweden: A nationwide study. Acta Neurologica Scandinavica, 2019, 140, 342-349.	1.0	38
76	Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101414.	0.9	16
77	Different epigenetic clocks reflect distinct pathophysiological features of multiple sclerosis. Epigenomics, 2019, 11, 1429-1439.	1.0	22
78	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	6.0	710
79	Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome. Journal of Neuroimmunology, 2019, 336, 577028.	1.1	3
80	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
81	Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis. Clinical Epigenetics, 2019, 11, 86.	1.8	24
82	A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2850-2862.	1.7	129
83	Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression. EBioMedicine, 2019, 43, 411-423.	2.7	45
84	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1565-1573.	1.4	11
85	Morvanâ€™s syndrome treated successfully with rituximab and lacosamide. BMJ Case Reports, 2019, 12, e226832.	0.2	5
86	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology, 2019, 26, 1060-1067.	1.7	27
87	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	0.7	5
88	B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine, 2019, 40, 517-527.	2.7	88
89	Increased peripheral levels of TARC/CCL17 in first episode psychosis patients. Schizophrenia Research, 2019, 210, 221-227.	1.1	8
90	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55

#	Article	IF	Citations
91	miRâ€31 regulates energy metabolism and is suppressed in TÂcells from patients with SjÃ¶gren's syndrome. European Journal of Immunology, 2019, 49, 313-322.	1.6	10
92	The association between multiple sclerosis and pain medications. Pain, 2019, 160, 424-432.	2.0	12
93	Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis â€“ Yes. Multiple Sclerosis Journal, 2018, 24, 1157-1159.	1.4	9
94	Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients. Schizophrenia Research, 2018, 199, 438-441.	1.1	8
95	The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. European Journal of Clinical Pharmacology, 2018, 74, 663-670.	0.8	17
96	Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers. Psychoneuroendocrinology, 2018, 89, 53-58.	1.3	25
97	Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients. Human Molecular Genetics, 2018, 27, 912-928.	1.4	41
98	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurology, 2018, 75, 320.	4.5	155
99	Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 202.e1-202.e6.	1.5	46
100	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	4.9	238
101	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. Multiple Sclerosis Journal, 2018, 24, 472-480.	1.4	30
102	CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Molecular Psychiatry, 2018, 23, 1244-1250.	4.1	44
103	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal, 2018, 24, 1046-1054.	1.4	149
104	Comparative effectiveness of rituximab relative to IFN-Î² or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis Journal, 2018, 24, 1087-1095.	1.4	44
105	Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis. Journal of Autoimmunity, 2018, 88, 43-49.	3.0	20
106	Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. European Journal of Clinical Pharmacology, 2018, 74, 219-226.	0.8	23
107	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal, 2018, 24, 1224-1233.	1.4	86
108	Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes. Multiple Sclerosis Journal, 2018, 24, 1288-1300.	1.4	33

#	Article	IF	Citations
109	Multiple sclerosis. Nature Reviews Disease Primers, 2018, 4, 43.	18.1	767
110	Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell, 2018, 175, 85-100.e23.	13.5	350
111	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177
112	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	0.7	627
113	Identification of MS-specific serum miRNAs in an international multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e491.	3.1	59
114	Increased number of monocytes and plasma levels of <scp>MCP</scp>â€1 and <scp>YKL</scp>â€40 in firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 432-440.	2.2	20
115	DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nature Communications, 2018, 9, 2397.	5.8	147
116	Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures. ENeuro, 2018, 5, ENEURO.0335-17.2018.	0.9	9
117	Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-ÎºB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution. Antioxidants and Redox Signaling, 2017, 26, 229-246.	2.5	41
118	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	1.4	81
119	Multiple Sclerosisâ€"A Tuning Fork Still Required. JAMA Neurology, 2017, 74, 264.	4.5	0
120	Population-based incidence and clinical characteristics of idiopathic intracranial hypertension. Acta Neurologica Scandinavica, 2017, 136, 427-433.	1.0	27
121	A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis. Mathematical Biosciences, 2017, 289, 1-8.	0.9	8
122	Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscular Disorders, 2017, 27, 565-568.	0.3	56
123	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 2017, 89, 2230-2237.	1.5	307
124	Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. Journal of Neuroimmunology, 2017, 312, 15-18.	1.1	46
125	1633â€...Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.1-A10.	0.9	0
126	Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology, 2017, 89, 578-585.	1.5	36

#	Article	IF	Citations
127	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304.	2.1	124
128	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurologica Scandinavica, 2017, 135, 17-24.	1.0	57
129	Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis â€“ a case report. Neuromuscular Disorders, 2017, 27, 90-93.	0.3	21
130	Effects of C2ta genetic polymorphisms on <scp>MHC</scp> class <scp>II</scp> expression and autoimmune diseases. Immunology, 2017, 150, 408-417.	2.0	4
131	The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis. Frontiers in Neurology, 2017, 8, 675.	1.1	43
132	The Immunobiology of Multiple Sclerosis. , 2016, , 180-191.		2
133	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology, 2016, 79, 950-958.	2.8	190
134	Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function. Clinical Immunology, 2016, 166-167, 89-95.	1.4	19
135	Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e219.	3.1	92
136	Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study. Multiple Sclerosis and Related Disorders, 2016, 10, 36-43.	0.9	9
137	Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Tollâ€like Receptor Stimulation in Peripheral Monocytes. Scandinavian Journal of Immunology, 2016, 84, 262-271.	1.3	32
138	T-cell activation and HLA-regulated response to smoking in the deep airways of patients with multiple sclerosis. Clinical Immunology, 2016, 169, 114-120.	1.4	17
139	Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions. Acta Neurologica Scandinavica, 2016, 134, 47-54.	1.0	72
140	Rituximab in multiple sclerosis. Neurology, 2016, 87, 2074-2081.	1.5	278
141	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	3.8	24
142	Reply. Annals of Neurology, 2016, 80, 791-792.	2.8	0
143	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e191.	3.1	69
144	Rituximab in paediatric onset multiple sclerosis: a case series. Journal of Neurology, 2016, 263, 322-326.	1.8	42

#	Article	IF	Citations
145	High-intensity resistance training in multiple sclerosis â€" An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition. Journal of the Neurological Sciences, 2016, 362, 251-257.	0.3	59
146	Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 85-93.	1.4	32
147	Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain, Behavior, and Immunity, 2016, 51, 47-55.	2.0	56
148	No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination. PLoS ONE, 2016, 11, e0154296.	1.1	2
149	High-intensity resistance training in multiple sclerosisâ€"an exploratory study. Physiotherapy, 2015, 101, e747.	0.2	0
150	Complement receptor 2 is up regulated in the spinal cord following nerve root injury and modulates the spinal cord response. Journal of Neuroinflammation, 2015, 12, 192.	3.1	9
151	Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology, 2015, 7, 181.	1.5	272
152	Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations. Molecular Medicine, 2015, 21, 769-781.	1.9	52
153	Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1271-1279.	1.4	43
154	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
155	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	1.4	56
156	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
157	P300 amplitude and response speed relate to preserved cognitive function in relapsingâ€"remitting multiple sclerosis. Clinical Neurophysiology, 2015, 126, 689-697.	0.7	25
158	Age-dependent effects on the treatment response of natalizumab in MS patients. Multiple Sclerosis Journal, 2015, 21, 48-56.	1.4	19
159	MicroRNAs as promising novel biomarkers and potential drug targets for inflammatory neurological diseases. Journal of the Neurological Sciences, 2015, 356, 3-4.	0.3	3
160	The autoimmune spectrum of myasthenia gravis: a Swedish populationâ€based study. Journal of Internal Medicine, 2015, 277, 594-604.	2.7	89
161	Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. PLoS ONE, 2015, 10, e0122048.	1.1	52
162	Is a Cancer Diagnosis Associated with Subsequent Risk of Transient Global Amnesia?. PLoS ONE, 2015, 10, e0122960.	1.1	6

#	Article	IF	Citations
163	Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS ONE, 2015, 10, e0132177.	1.1	114
164	Variability in the CIITA gene interacts with HLA in multiple sclerosis. Genes and Immunity, 2014, 15, 162-167.	2.2	10
165	Unbiased Expression Mapping Identifies a Link between the Complement and Cholinergic Systems in the Rat Central Nervous System. Journal of Immunology, 2014, 192, 1138-1153.	0.4	9
166	High interleukin-6 and impulsivity: determining the role of endophenotypes in attempted suicide. Translational Psychiatry, 2014, 4, e470-e470.	2.4	68
167	Phenotypes and Predictors of Pain Following Traumatic Spinal Cord Injury: A Prospective Study. Journal of Pain, 2014, 15, 40-48.	0.7	194
168	Methylome characterization of CD4+ T cells in multiple sclerosis â€" Establishing a role for miR-21 in autoimmune disease. Journal of Neuroimmunology, 2014, 275, 112.	1.1	0
169	A changing treatment landscape for multiple sclerosis: challenges and opportunities. Journal of Internal Medicine, 2014, 275, 364-381.	2.7	50
170	Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nature Communications, 2014, 5, 5056.	5.8	137
171	Genetic variability in the rat Aplec C-type lectin gene cluster regulates lymphocyte trafficking and motor neuron survival after traumatic nerve root injury. Journal of Neuroinflammation, 2013, 10, 60.	3.1	9
172	Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2465-2481.	1.5	48
173	The DQB1(*)03:02 HLA haplotype is associated with increased risk of chronic pain after inguinal hernia surgery and lumbar disc herniation. Scandinavian Journal of Pain, 2013, 4, 258-258.	0.5	0
174	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
175	Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis. Archives of Clinical Neuropsychology, 2013, 28, 144-155.	0.3	46
176	Naturally Occurring Variation in the Glutathione-S-Transferase 4 Gene Determines Neurodegeneration After Traumatic Brain Injury. Antioxidants and Redox Signaling, 2013, 18, 784-794.	2.5	25
177	Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat. Brain, Behavior, and Immunity, 2013, 27, 109-122.	2.0	46
178	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis Journal, 2013, 19, 765-774.	1.4	66
179	Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. Multiple Sclerosis Journal, 2013, 19, 863-870.	1.4	18
180	Regulated Extracellular Choline Acetyltransferase Activityâ€" The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway. PLoS ONE, 2013, 8, e65936.	1.1	72

#	Article	IF	Citations
181	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. PLoS ONE, 2013, 8, e57820.	1.1	213
182	Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers. PLoS ONE, 2013, 8, e63172.	1.1	69
183	Autologous Hematopoietic Stem Cell Transplantation In Neuromyelitis Optica: A Retrospective Study Of The EBMT Autoimmune Diseases Working Party In Collaboration With The University Of Sao Paulo, Ribeirao Preto, Brazil. Blood, 2013, 122, 2125-2125.	0.6	3
184	The Calcitonin Receptor Gene Is a Candidate for Regulation of Susceptibility to Herpes simplex Type 1 Neuronal Infection Leading to Encephalitis in Rat. PLoS Pathogens, 2012, 8, e1002753.	2.1	12
185	Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Translational Psychiatry, 2012, 2, e196-e196.	2.4	75
186	Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes. Genes and Immunity, 2012, 13, 632-640.	2.2	24
187	Genetic and sex influence on neuropathic painâ€like behaviour after spinal cord injury in the rat. European Journal of Pain, 2012, 16, 1368-1377.	1.4	24
188	Naturally Occurring Genetic Variability in Expression of Gsta4 is Associated with Differential Survival of Axotomized Rat Motoneurons. NeuroMolecular Medicine, 2012, 14, 15-29.	1.8	12
189	iNOS-mediated secondary inflammatory response differs between rat strains following experimental brain contusion. Acta Neurochirurgica, 2012, 154, 689-697.	0.9	13
190	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
191	Both MHC and non-MHC genes regulate inflammation and T-cell response after traumatic brain injury. Brain, Behavior, and Immunity, 2011, 25, 981-990.	2.0	20
192	The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis. PLoS ONE, 2011, 6, e19138.	1.1	33
193	Inflammatory and haemostatic markers in idiopathic intracranial hypertension. Journal of Internal Medicine, 2011, 270, 496-499.	2.7	5
194	Concomitant autoimmunity in myasthenia gravis â€" Lack of association with IgA deficiency. Journal of Neuroimmunology, 2011, 236, 118-122.	1.1	26
195	Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurological Sciences, 2011, 31, 289-293.	0.9	58
196	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Annals of Neurology, 2011, 69, 83-89.	2.8	295
197	Profiling of CD4+ T Cells with Epigenetic Immune Lineage Analysis. Journal of Immunology, 2011, 186, 92-102.	0.4	86
198	A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 708-719.	1.4	98

#	Article	IF	Citations
199	Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Multiple Sclerosis Journal, 2011, 17, 335-343.	1.4	213
200	High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction?. Journal of Lipid Research, 2011, 52, 170-174.	2.0	18
201	Genetic regulation of microglia activation, complement expression, and neurodegeneration in a rat model of traumatic brain injury. Experimental Brain Research, 2010, 205, 103-114.	0.7	32
202	Influence of Perineurial Cells and Toll-Like Receptors 2 and 9 on Herpes simplex Type 1 Entry to the Central Nervous System in Rat Encephalitis. PLoS ONE, 2010, 5, e12350.	1.1	13
203	Fine Mapping of Gene Regions Regulating Neurodegeneration. PLoS ONE, 2009, 4, e5906.	1.1	8
204	Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta. Journal of Neuroimmunology, 2009, 212, 44-52.	1.1	5
205	Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury. Journal of Neuroimmunology, 2009, 212, 82-92.	1.1	13
206	The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatmentâ€sensitive biomarkers. European Journal of Neurology, 2009, 16, 528-536.	1.7	84
207	Inflammation and susceptibility to neurodegeneration: The use of unbiased genetics to decipher critical regulatory pathways. Neuroscience, 2009, 158, 1143-1150.	1.1	13
208	Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis. Journal of NeuroVirology, 2008, 14, 102-118.	1.0	12
209	Both MHC and non-MHC genes regulate development of experimental neuropathic pain in rats. Neuroscience Letters, 2008, 442, 284-286.	1.0	5
210	Genetic analysis of neuropathic pain-like behavior following peripheral nerve injury suggests a role of the major histocompatibility complex in development of allodynia. Pain, 2008, 136, 313-319.	2.0	32
211	Vra4 Congenic Rats with Allelic Differences in the Class II Transactivator Gene Display Altered Susceptibility to Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 180, 3289-3296.	0.4	18
212	The axon reaction: Identifying the genes that make a difference. Physiology and Behavior, 2007, 92, 67-74.	1.0	4
213	Recovery from spinal cord injury differs between rat strains in a major histocompatibility complexâ€independent manner. European Journal of Neuroscience, 2007, 26, 1118-1127.	1.2	13
214	200 THE MAJOR HISTOCOMPATIBILITY COMPLEX INFLUENCES NEUROPATHIC PAIN-LIKE BEHAVIORS IN RATS AFTER SCIATIC NERVE ISCHEMIC INJURY. European Journal of Pain, 2006, 10, S55-S55.	1.4	0
215	Decreased Expression of VEGF-A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis. Scandinavian Journal of Immunology, 2006, 64, 609-622.	1.3	36
216	Genetics of autoimmune neuroinflammation. Current Opinion in Immunology, 2006, 18, 643-649.	2.4	18

#	Article	IF	Citations
217	Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes. Neurobiology of Disease, 2006, 24, 67-88.	2.1	16
218	MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nature Genetics, 2005, 37, 486-494.	9.4	276
219	Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems. Journal of Neuroimmunology, 2005, 164, 93-104.	1.1	30
220	Genetic dissection of neurodegeneration and CNS inflammation. Journal of the Neurological Sciences, 2005, 233, 99-108.	0.3	16
221	From The Cover: A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17843-17848.	3.3	233
222	Prior poliomyelitisâ€"Ivlg treatment reduces proinflammatory cytokine production. Journal of Neuroimmunology, 2004, 150, 139-144.	1.1	42
223	T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis. Journal of Immunology, 2004, 172, 7169-7176.	0.4	200
224	Increased Brain-Derived Neurotrophic Factor Expression in White Blood Cells of Relapsing-Remitting Multiple Sclerosis Patients. Scandinavian Journal of Immunology, 2003, 57, 493-497.	1.3	98
225	Discrete Gene Loci Regulate Neurodegeneration, Lymphocyte Infiltration, and Major Histocompatibility Complex Class II Expression in the CNS. Journal of Neuroscience, 2003, 23, 9817-9823.	1.7	40
226	Differential Expression of the Chemokine Receptors CX₃CR1 and CCR1 by Microglia and Macrophages in Myelinâ€Oligodendrocyteâ€Glycoproteinâ€Induced Experimental Autoimmune Encephalomyelitis. Brain Pathology, 2003, 13, 617-629.	2.1	37
227	Upregulation of VEGF-A Without Angiogenesis in a Mouse Model of Dilated Cardiomyopathy Caused by Mitochondrial Dysfunction. Journal of Histochemistry and Cytochemistry, 2002, 50, 935-944.	1.3	28
228	Facial nerve lesion response; strain differences but no involvement of IFN-Î³, STAT4 or STAT6. NeuroReport, 2002, 13, 1589-1593.	0.6	17
229	Properties of motoneurons underlying their regenerative capacity after axon lesions in the ventral funiculus or at the surface of the spinal cord. Brain Research Reviews, 2002, 40, 309-316.	9.1	36
230	Differential Expression of Neurotrophic Factors and Inflammatory Cytokines by Myelin Basic Protein-Specific and Other Recruited T Cells Infiltrating the Central Nervous System during Experimental Autoimmune Encephalomyelitis. Scandinavian Journal of Immunology, 2002, 55, 264-273.	1.3	51
231	Menin Interacts Directly with the Homeobox-Containing Protein Pem. Biochemical and Biophysical Research Communications, 2001, 286, 426-431.	1.0	92
232	Neuroinflammation in the rat - CNS cells and their role in the regulation of immune reactions. Immunological Reviews, 2001, 184, 212-225.	2.8	48
233	Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains. Journal of Comparative Neurology, 2001, 431, 75-87.	0.9	47
234	Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by nonâ€MHC genes in congenic inbred rat strains. Journal of Comparative Neurology, 2001, 431, 75-87.	0.9	2

#	Article	IF	Citations
235	Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains. Journal of Comparative Neurology, 2001, 431, 75-87.	0.9	12
236	Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse. International Journal of Molecular Medicine, 2001, 8, 681-9.	1.8	5
237	Differential regulation of trophic factor receptor mRNAs in spinal motoneurons after sciatic nerve transection and ventral root avulsion in the rat. Journal of Comparative Neurology, 2000, 426, 587-601.	0.9	96
238	Regulation of laminin-associated integrin subunit mRNAs in rat spinal motoneurons during postnatal development and after axonal injury. Journal of Comparative Neurology, 2000, 428, 294-304.	0.9	43
239	Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration. European Journal of Neuroscience, 2000, 12, 3675-3686.	1.2	97
240	Genetics of rat neuroinflammation. Journal of Neuroimmunology, 2000, 107, 191-200.	1.1	32
241	Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. Journal of Neuroimmunology, 2000, 103, 202-210.	1.1	48
242	Molecular characterization of human and murine C11orf5, a new member of the FAUNA gene cluster. Mammalian Genome, 2000, 11, 78-80.	1.0	1
243	Neuroprotection by Encephalomyelitis: Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNS-Infiltrating T and Natural Killer Cells. Journal of Neuroscience, 2000, 20, 5283-5291.	1.7	293
244	Genetic Regulation of Nerve Avulsionâ€Induced Spinal Cord Inflammation. Annals of the New York Academy of Sciences, 2000, 917, 186-196.	1.8	10
245	Expression of nonclassical MHC class I (RT1-U) in certain neuronal populations of the central nervous system. European Journal of Neuroscience, 1999, 11, 4468-4472.	1.2	54
246	Expression of MHC class I heavy chain and Î²2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons. Journal of Neuroimmunology, 1999, 101, 76-86.	1.1	76
247	Non-MHC gene regulation of nerve root injury induced spinal cord inflammation and neuron death. Journal of Neuroimmunology, 1999, 101, 87-97.	1.1	38
248	Restricted Expression Pattern ofvegf-din the Adult and Fetal Mouse: High Expression in the Embryonic Lung. Biochemical and Biophysical Research Communications, 1999, 257, 891-894.	1.0	45
249	Characterization of the mouse Men1 gene and its expression during development. Oncogene, 1998, 17, 2485-2493.	2.6	133
250	Strain dependent differences in the inflammatory response to mechanical nerve injuries. Journal of Neuroimmunology, 1998, 90, 30.	1.1	0
251	Regulatory effects of trophic factors on expression and distribution of CGRP and GAP-43 in rat motoneurons. , 1998, 51, 1.		31
252	Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries. , 1998, 400, 57-72.		67

#	Article	IF	Citations
253	Characterization of the human synaptogyrin gene family. Human Genetics, 1998, 103, 131-141.	1.8	54
254	Mapping of the human Ca2+ channel Î²4 subunit to 2q22-23 and its expression in developing mouse. Mammalian Genome, 1998, 9, 310-311.	1.0	0
255	Expression and chromosomal localization of the Requiem gene. Mammalian Genome, 1998, 9, 660-665.	1.0	22
256	Changes in the mRNA expression pattern, with special reference to calcitonin gene-related peptide, after axonal injuries in rat motoneurons depends on age and type of injury. Experimental Brain Research, 1998, 119, 191-204.	0.7	53
257	VAMPâ€1 and VAMPâ€2 gene expression in rat spinal motoneurones: differential regulation after neuronal injury. European Journal of Neuroscience, 1998, 10, 301-316.	1.2	27
258	Expression of theBCL6Gene in the Pre- and Postnatal Mouse. Biochemical and Biophysical Research Communications, 1998, 247, 357-360.	1.0	39
259	Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries. Journal of Comparative Neurology, 1998, 400, 57-72.	0.9	23
260	Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas. Leukemia, 1997, 11, 594-598.	3.3	18
261	Differential subcellular localization of SNAP-25a and SNAP-25b RNA transcripts in spinal motoneurons and plasticity in expression after nerve injury. Molecular Brain Research, 1996, 37, 49-62.	2.5	23
262	Expression of the VEGF-Related Factor Gene in Pre- and Postnatal Mouse. Biochemical and Biophysical Research Communications, 1996, 220, 147-152.	1.0	23
263	Sequence and Expression of the Mouse Homologue to Human Phospholipase C Î²3 Neighboring Gene. Biochemical and Biophysical Research Communications, 1996, 223, 335-340.	1.0	8
264	GDNF mRNA in Schwann cells and DRG satellite cells after chronic sciatic nerve injury. NeuroReport, 1996, 7, 857-860.	0.6	187
265	Expression of the phosphoinositide-specific phospholipase CÎ²3 gene in the rat. NeuroReport, 1995, 6, 2542-2544.	0.6	9
266	Increase in Î±-CGRP and GAP-43 in aged motoneurons: A study of peptides, growth factors, and ChAT mRNA in the lumbar spinal cord of senescent rats with symptoms of hindlimb incapacities. Journal of Comparative Neurology, 1995, 359, 69-89.	0.9	53
267	Expression of NMDA Receptor mRNAs in Rat Motoneurons is Down-regulated after Axotomy. European Journal of Neuroscience, 1995, 7, 2101-2110.	1.2	82
268	Fibroblast Growth Factors Regulate Calcitonin Gene-related Peptide mRNA Expression in Rat Motoneurons after Lesion and in Culture. European Journal of Neuroscience, 1995, 7, 1739-1750.	1.2	65
269	Prominent Expression of bFGF in Dorsal Root Ganglia after Axotomy. European Journal of Neuroscience, 1995, 7, 2458-2468.	1.2	58
270	trkC-like Immunoreactivity in the Primate Descending Serotoninergic System. European Journal of Neuroscience, 1994, 6, 230-236.	1.2	18

#	Article	IF	Citations
271	Increased trkB mRNA expression by axotomized motoneurones. NeuroReport, 1994, 5, 697-700.	0.6	64
272	Calcitonin gene-related peptide-like immunoreactivity in motoneuron pools innervating different hind limb muscles in the rat. Experimental Brain Research, 1993, 96, 291-303.	0.7	41
273	Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin. Experimental Brain Research, 1993, 93, 450-61.	0.7	63
274	GAP-43, aFGF, CCK and Î±- and Î²-CGRP in Rat Spinal Motoneurons Subjected to Axotomy and/or Dorsal Root Severance. European Journal of Neuroscience, 1993, 5, 1321-1333.	1.2	61
275	The peptidergic motoneurone. NeuroReport, 1993, 4, 849-856.	0.6	39
276	Calcitonin Gene-Related Peptide in the Brain, Spinal Cord, and Some Peripheral Systems. Annals of the New York Academy of Sciences, 1992, 657, 119-134.	1.8	113
277	Reappearance of calcitonin gene-related peptide-like immunoreactivity in the dorsal horn in long-term dorsal root transected rat. Brain Research, 1992, 585, 400-404.	1.1	16
278	Expression of GAP-43 mRNA in the adult mammalian spinal cord under normal conditions and after different types of lesions, with special reference to motoneurons. Experimental Brain Research, 1992, 91, 284-95.	0.7	77
279	Calcitonin Gene-related Peptide (CGRP)-like Immunoreactivity and CGRP mRNA in Rat Spinal Cord Motoneurons after Different Types of Lesions. European Journal of Neuroscience, 1991, 3, 737-757.	1.2	67
280	Peripheral nerve section induces increased levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity in axotomized motoneurons. Experimental Brain Research, 1990, 79, 212-6.	0.7	93